{"id":"W4382513940","doi":"10.1097/01.hs9.0000936124.56965.24","title":"B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Regimen; Internal medicine; Dexamethasone; Ixazomib; Oncology; Multiple myeloma; Carfilzomib; Clinical endpoint; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001095034,0.0004857717,0.002399844,0.0003100264,0.0001701069,0.00005526216,0.0001172568,0.0002301768,0.0003815937],"category_scores_gemma":[0.003268078,0.0003274175,0.000328518,0.0006686717,0.0002401122,0.0001794314,0.00008069305,0.0004259892,0.00009036094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000326702,"about_ca_system_score_gemma":0.0003880141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006657931,"about_ca_topic_score_gemma":0.0001795277,"domain_scores_codex":[0.9958372,0.0005580396,0.0009262025,0.0007243687,0.001139574,0.0008146791],"domain_scores_gemma":[0.9962434,0.002031939,0.00031891,0.000588682,0.0002701795,0.0005468489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.984944,0.001616909,0.005373714,0.00008310036,0.001125719,0.0006809466,0.0003386124,0.000003499,0.0005490213,0.00001531281,0.001203574,0.004065562],"study_design_scores_gemma":[0.9841958,0.008152865,0.003724379,0.0002215854,0.000391595,0.000003039,0.0002447987,0.001265752,0.0006084433,0.00001672501,0.0008678517,0.0003071914],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848542,0.0004575742,0.00001894666,0.0002990963,0.0003529367,0.01216668,0.00008244991,0.0002179281,0.001550187],"genre_scores_gemma":[0.994318,0.000198758,0.0005777427,0.00005275162,0.0001209476,0.001433896,0.0003581726,0.00009065207,0.002849085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01073278,"threshold_uncertainty_score":0.9999178,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02313725160101678,"score_gpt":0.3011518509707363,"score_spread":0.2780145993697196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}